64,996 Merck & Co., Inc. $MRK Shares Sold by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd trimmed its stake in Merck & Co., Inc. (NYSE:MRK) by 9.4% in the third quarter, HoldingsChannel.com reports. The fund owned 629,819 shares of the company’s stock after selling 64,996 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Merck & Co., Inc. were worth $91,519,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in MRK. Bullseye Investment Management LLC acquired a new stake in shares of Merck & Co., Inc. during the second quarter valued at $27,000. Horizons Wealth Management purchased a new stake in Merck & Co., Inc. during the 3rd quarter worth about $30,000. Graney & King LLC raised its stake in Merck & Co., Inc. by 400.0% in the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock valued at $32,000 after purchasing an additional 200 shares during the last quarter. Montgomery Financial Services LLC acquired a new position in Merck & Co., Inc. in the 2nd quarter valued at about $41,000. Finally, Evergreen Advisors LLC acquired a new position in Merck & Co., Inc. in the 1st quarter valued at about $43,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Investors are evaluating Merck & Co.’s Phase 3 melanoma results, which could influence expectations for the company’s oncology pipeline and future growth beyond Keytruda. The market’s reaction will depend on the trial’s efficacy, safety and regulatory implications. How Investors Are Reacting To Merck Phase 3 Melanoma Results
• Neutral Sentiment: Analysts continue to view Merck’s dividend as an important part of the investment case, supported by its global pharmaceutical portfolio and Keytruda franchise. However, the income outlook is tied to the company’s ability to offset future Keytruda-related competitive and patent pressures. Merck’s 2.4% Dividend Yield: A Reliable Income Stream or a Risky Bet on Recovery?
• Neutral Sentiment: Merck is being discussed alongside other healthcare companies benefiting from artificial-intelligence-driven diagnostics, sequencing and drug development. The theme may support long-term sector interest, but the article does not identify a specific near-term catalyst for MRK. The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
• Negative Sentiment: Exchange-traded funds were net sellers of MRK on October 16, adding technical selling pressure and potentially contributing to weaker trading. ETFs Are Net Sellers of Merck on Oct. 16
• Negative Sentiment: Merck & Co. underperformed a stronger overall market in the latest session, reflecting investor caution despite its recent revenue growth and raised 2026 sales outlook. Merck Stock Dips While Market Gains
• Neutral Sentiment: Merck KGaA agreed to acquire Silence Therapeutics for $20 per American depositary share, a 130% premium. The deal drove SLN sharply higher but does not represent an acquisition by Merck & Co. (NYSE: MRK), so its direct impact on MRK is limited.

Wall Street Analysts Forecast Growth

MRK has been the topic of a number of recent research reports. Bank of America upped their target price on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Daiwa Securities Group upgraded shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target for the company in a report on Wednesday, August 12th. Wolfe Research boosted their price objective on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research report on Tuesday, August 25th. Guggenheim boosted their price objective on shares of Merck & Co., Inc. from $146.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday, September 8th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Merck & Co., Inc. from $150.00 to $165.00 and gave the company an “overweight” rating in a research note on Monday, October 5th. Seventeen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $151.92.

Merck & Co., Inc. Price Performance

MRK opened at $143.58 on Tuesday. The company’s 50 day simple moving average is $145.86 and its 200 day simple moving average is $129.48. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. Merck & Co., Inc. has a 1 year low of $82.01 and a 1 year high of $156.92. The stock has a market capitalization of $354.24 billion, a PE ratio of 114.86, a P/E/G ratio of 6.74 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same period in the previous year, the firm earned $2.13 earnings per share. Merck & Co., Inc.’s revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts expect that Merck & Co., Inc. will post 2.66 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Insider Activity at Merck & Co., Inc.

In related news, EVP Chirfi Guindo sold 10,000 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the transaction, the executive vice president directly owned 36,613 shares of the company’s stock, valued at approximately $4,942,755. This trade represents a 21.45% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP David R. Maraldo sold 18,706 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the transaction, the executive vice president owned 18,212 shares in the company, valued at $2,344,248.64. The trade was a 50.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.